-
My Account
My Account
BSE Live
Apr 09, 16:00Prev. Close
614.30
Open Price
615.00
Bid Price (Qty.)
636.95 (50)
Offer Price (Qty.)
636.95 (695)
NSE Live
Apr 09, 15:59Prev. Close
614.25
Open Price
613.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
636.75 (2197)
| Yearly Results of Sun Pharmaceutical Industries (in Rs. Cr.) | Mar '20 | Mar '19 | Mar '18 | Mar '17 | Mar '16 | |
| Net Sales/Income from operations | 11,906.74 | 9,783.29 | 7,696.33 | 7,523.79 | 7,254.09 | |
| Other Operating Income | 625.19 | 519.92 | 251.27 | 282.91 | 609.60 | |
| Total Income From Operations | 12,531.93 | 10,303.21 | 7,947.60 | 7,806.70 | 7,863.69 | |
| EXPENDITURE | ||||||
| Consumption of Raw Materials | 3,201.71 | 2,727.71 | 2,167.52 | 2,284.52 | 1,838.31 | |
| Purchase of Traded Goods | 1,227.41 | 1,196.85 | 1,165.99 | 1,236.50 | 1,170.00 | |
| Increase/Decrease in Stocks | 138.60 | -251.30 | 159.26 | -162.79 | -14.38 | |
| Power & Fuel | -- | -- | -- | -- | -- | |
| Employees Cost | 1,702.77 | 1,571.34 | 1,617.69 | 1,486.17 | 1,476.69 | |
| Depreciation | 561.56 | 552.95 | 432.23 | 418.56 | 464.25 | |
| Excise Duty | -- | -- | -- | -- | -- | |
| Admin. And Selling Expenses | -- | -- | -- | -- | -- | |
| R & D Expenses | -- | -- | -- | -- | -- | |
| Provisions And Contingencies | -- | -- | -- | -- | -- | |
| Exp. Capitalised | -- | -- | -- | -- | -- | |
| Other Expenses | 3,549.79 | 3,302.35 | 2,714.12 | 2,867.03 | 3,811.74 | |
| P/L Before Other Inc. , Int., Excpt. Items & Tax | 2,150.09 | 1,203.31 | -309.21 | -323.29 | -882.92 | |
| Other Income | 1,510.92 | 1,271.44 | 1,128.04 | 514.41 | 445.09 | |
| P/L Before Int., Excpt. Items & Tax | 3,661.01 | 2,474.75 | 818.83 | 191.12 | -437.83 | |
| Interest | 408.01 | 540.92 | 388.31 | 223.56 | 574.10 | |
| P/L Before Exceptional Items & Tax | 3,253.00 | 1,933.83 | 430.52 | -32.44 | -1,011.93 | |
| Exceptional Items | -- | -1,214.38 | -950.50 | -- | -70.13 | |
| P/L Before Tax | 3,253.00 | 719.45 | -519.98 | -32.44 | -1,082.06 | |
| Tax | 41.86 | -97.15 | -25.39 | 2.51 | 5.45 | |
| P/L After Tax from Ordinary Activities | 3,211.14 | 816.60 | -494.59 | -34.95 | -1,087.51 | |
| Prior Year Adjustments | -- | -- | -- | -- | -- | |
| Extra Ordinary Items | -- | -- | -- | -- | -- | |
| Net Profit/(Loss) For the Period | 3,211.14 | 816.60 | -494.59 | -34.95 | -1,087.51 | |
| Equity Share Capital | 239.93 | 239.93 | 239.93 | 239.93 | 240.66 | |
| Reserves Excluding Revaluation Reserves | 24,156.29 | 22,603.68 | 22,082.68 | 20,772.54 | 21,242.43 | |
| Equity Dividend Rate (%) | 400.00 | 275.00 | 200.00 | 350.00 | 100.00 | |
| EPS Before Extra Ordinary | ||||||
| Basic EPS | 13.38 | 3.40 | -2.10 | -0.10 | -4.50 | |
| Diluted EPS | 13.38 | 3.40 | -2.10 | -0.10 | -4.50 | |
| EPS After Extra Ordinary | ||||||
| Basic EPS. | 13.38 | 3.40 | -2.10 | -0.10 | -4.50 | |
| Diluted EPS. | 13.38 | 3.40 | -2.10 | -0.10 | -4.50 | |
| Public Share Holding | ||||||
| No Of Shares (Crores) | -- | -- | -- | -- | -- | |
| Share Holding (%) | -- | -- | -- | -- | -- | |
| Promoters and Promoter Group Shareholding | ||||||
| a) Pledged/Encumbered | ||||||
| - Number of shares (Crores) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | -- | -- | |
| b) Non-encumbered | ||||||
| - Number of shares (Crores). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total sh. of prom. and promoter group). | -- | -- | -- | -- | -- | |
| - Per. of shares (as a % of the total Share Cap. of the company). | -- | -- | -- | -- | -- |
05.04.2021
Buy Sun Pharmaceutical Industries: target of Rs 700: Sharekhan
10.03.2021
Sun Pharma share price rise over 2% after arm acquires stake in WRS Bioproducts
12.02.2021
Sun Pharma share price falls on settlement order by SEBI, here is what brokerages have to say
09.02.2021
Buy Sun Pharmaceutical Industries; target of Rs 700: Sharekhan
02.02.2021
Sun Pharma Consolidated December 2020 Net Sales at Rs 8,836.78 crore, up 8.36% Y-o-Y
02.02.2021
Sun Pharma Standalone December 2020 Net Sales at Rs 3,388.02 crore, up 12.43% Y-o-Y
29.01.2021
Sun Pharma beats estimates in Q3 as profit doubles to Rs 1,852.5 crore
04.11.2020
Sun Pharma Consolidated September 2020 Net Sales at Rs 8,553.13 crore, up 5.29% Y-o-Y
29.01.2021
Sun Pharma's profit, revenue to rise in Q3; EBITDA margin may remain stable
22.01.2021
Sun Pharma Q3 PAT seen up 56.7% YoY to Rs. 1,431.5 cr: Yash Securities
18.01.2021
Sun Pharma Q3 PAT seen up 44.4% YoY to Rs 1,319 cr: ICICI Direct
03.11.2020
Sun Pharma Q2 preview: Taro may hit revenue growth, trends in specialty portfolio key to watch
